$9 million grant for prostate cancer research

Henry Ford Hospital is embarking on an expanded major clinical trial involving the use of gene therapy in combination with radiation therapy, to determine if the combined treatment is more effective than radiation therapy alone for patients with intermediate risk prostate cancer.

The clinical trial is part of a $9 million grant from the National Cancer Institute (NCI) awarded to Henry Ford to study the effectiveness of gene therapy to treat prostate cancer.

"As part of this research grant we have had encouraging results involving two smaller clinical studies," says Svend Freytag, Ph.D., division head of Research, Radiation Oncology, Henry Ford Hospital.

Dr. Freytag, along with Benjamin Movsas, M.D., chair of Radiation Oncology and Hans Stricker, M.D., vice chair of Urology at Henry Ford Hospital are the study's key researchers.

Because of the results from the previous trials, NCI approved a phase III trial involving 280 prostate cancer patients over a three-year period. A phase III trial is the final stage in a study to determine if the treatment being studied should become the standard treatment.

Currently radiation therapy (without the gene therapy) or surgical removal of the prostate is the standard treatment for patients with localized prostate cancer, with similar cure rates. Prostate Cancer is the second leading cause of cancer death for men according to the American Cancer Society.

"When you consider that across the world most trials involving gene therapy are in very early stages of development involving research in test tubes, the fact that Henry Ford Hospital is now embarking on a major phase III clinical trial to test this as a new standard treatment, is a testament to the world class innovative research taking place right here," says Dr. Movsas, principal investigator of the study. "To my knowledge, this is the only place in the world where such a gene therapy study is available for this group of patients," he adds.


(Editor compiled and published $9 million grant for prostate cancer research at HealthNewsTrack on February 8, 2008 sourced from Henry Ford Health System - http://www.henryfordhealth.org/)

Prostate cancer - recent articles and current news stories:

- IMRT Radiation optimal for localized prostate cancer
- Circumcision may protect you against prostate cancer
- PSA test helps predicting biopsy need and low risk prostate cancer
- More aggressive treatment not necessary for men with a family history of prostate cancer
- Alpharadin improved survival in advanced prostate cancer patients

Most related articles:

- $9 million grant for prostate cancer research
- Smoking may increase risk of prostate cancer recurrence - 6.6
- Coffee may reduce prostate cancer risk - 6.1
- Prostate cancer risk from heavy drinking - 6
- High insulin level increases prostate cancer risk - 5.9

More related articles:

- Grant, Prostate cancer, Research, Clinical trial, Gene therapy, Radiation therapy
- Dietary supplements discouraged for prostate cancer patients - 10.7
- Success with ipilimumab in prostate cancer patients - 10.6
- IMRT Radiation optimal for localized prostate cancer - 10.5
- Prostate cancer family history has no impact on treatment - 10.4

Prostate cancer related articles:

- Prostate cancer risk from heavy drinking - 6
- High insulin level increases prostate cancer risk - 5.9
- Circumcision may protect you against prostate cancer - 5.8
- Smoking may increase risk of prostate cancer recurrence - 5.7
- Prostate biopsy is not always necessary after raised PSA levels - 5.7

Prostate cancer article/news source:

Read more health articles from Henry Ford Health System and health articles from USA.

Prostate cancer - search related terms:

Clinical trial, Gene therapy, Grant, Prostate cancer, Radiation therapy, Research,
Prostate cancer books,

List health news, Health organizations, Health news world, Glossary, Best health articles, Featured     Go to top

The information provided on Health Newstrack is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician. We comply with the HONcode principles for trustworthy health information, and Health News Track is hon code accredited, verify here.
About us, Site map Privacy policy, Disclaimer
© 2007, 2008, 2009, 2010, 2011 HealthNewsTrack.com
4.51